In the present study, we examined BCL11A at the genomic and transcriptional levels in PMBLs and, for the first time, proceeded to a study of BCL11A XL protein expression analysis in these tumors. To this end, PMBLs with (n ¼ 5) or without (n ¼ 15) gains/amplifications of 2p13-p16 by CGH, respectively, were analyzed. Additionally, we included the two PMBL cell lines MedB-1 and Karpas1106 and performed fluorescence in situ hybridization (FISH), quantitative real-time polymerase chain reaction (qRT-PCR) for mRNA and immunolabeling for protein detection (see Supplementary Information).
A previous study of DLBCL revealed that cases with 2p14-p16 gains or amplifications by CGH also showed gains or amplifications of the BCL11A and REL genes by RQ-PCR that were in same range as the genomic overrepresentations. However, one DLBCL sample despite having a normal chromosome 2 CGH profile exhibited gains of both these genes. 6 Conversely, and surprisingly, a subset of PMBLs with gains of 2p14-p16 by CGH had normal gene copy numbers for both BCL11A and REL. Our genomic analysis by FISH using specific probes for the BCL11A and REL loci, as described previously, 2 confirmed our CGH results of the PMBL cases 1, 2 and 5 with high-level amplifications at 2p13-p16 and PMBL cases 3 and 4 with gains of 2p13-p16. In addition, we detected amplifications (median copy number 46) of BCL11A in two further PMBLs (6 and 17) and gains (median copy number 3-6) in a further eight PMBLs (7-14) (Figure 1a ), all of which had a normal 2p chromosome profile by CGH. The PMBL line MedB-1 showed an amplification of BCL11A in a subset of cells. Karpas1106 had a gain of BCL11A (Table 1) . Thus, 15/20 (75%) PMBLs displayed an increased BCL11A gene copy number rendering it the most frequent genomic aberration in PMBL detected so far.
The mRNA expression of several target genes at 2p14-p16 including BCL11A has previously been analyzed in GCB-DLBCL, ABC-DLBCL and PMBL. 1 Despite increased gene copy numbers in the chromosomal region 2p14-p16, the transcripts were upregulated for only some of the target genes examined in these samples. BCL11A transcripts were not upregulated, in either the GCB or in the ABC subtypes. The mRNA data on PMBLs were lacking in this study. 1 To detect BCL11A transcripts by qRT-PCR, we used a primer pair recognizing a sequence common to the BCL11A S , BCL11A L and BCL11A XL variants. We found high-level expression of BCL11A transcripts in two of five PMBLs (2 and 5) with genomic amplifications, based on the levels in lymphoid tissue (herein referred to as the normal expression range; Figure 1b) . The BCL11A transcript levels in four of 10 PMBLs with genomic gains also exceeded the normal expression range, although levels were lower than in cases with amplifications. For two of five PMBLs with the normal two signals by FISH and the MedB-1 and Karpas1106 cell lines, the transcript levels for BCL11A remained below the normal expression range.
To analyze BCL11A XL protein expression in the PMBL cases, we utilized the recently described murine monoclonal antibody BCL11A/123 specific for the BCL11A XL isoform. 7 Paraffinembedded tissue sections from 16/20 PMBLs and cell pellets from the PMBL cell lines were available for immunochemical analysis. BCL11A XL immunolabeling was evaluated against the strongly positive cells of the mantle zone. 7 In general, immunolabeling presented a heterogeneous BCL11A XL staining pattern across the lymphomas in that both the proportion of positive cells and the staining intensity were variable (Table 1 and Figure 1c) .
Interestingly, we found nuclear BCL11A XL protein in 14/16 (87.5%) PMBLs (Table 1) . A similar frequency of BCL11A XL protein expression has recently been observed in 82% GCBDLBCLs and in 70% ABC-DLBCLs. 7 Previously, in these entities, gains including amplifications of 2p14-p16 target genes were shown not to provoke upregulated transcription of several target genes including BCL11A by expression profiling. 1 In eight of the 14 PMBLs, nuclear staining was detectable in more than 70% of the cells. Intriguingly, seven of these had genomic gains/ amplifications of BCL11A, whereas one, PMBL 20, had normal BCL11A gene copy number. Conversely, BCL11A XL immunostaining turned out to be completely negative only for PMBLs 6 and 7 despite these two cases having amplified and gained BCL11A gene copy numbers, respectively. The PMBL cell lines also completely lacked nuclear BCL11A XL protein by immunostaining. In sum, 4/16 (25%) PMBLs (3, 5, 11 and 12) revealed a clear correlation between increased gene copy numbers, increased transcript levels and nuclear staining in the majority of the cells. Thus, there is no overall correlation between genomic, transcript and protein levels in PMBLs. Hence, further regulatory mechanisms for the BCL11A XL positivity have to be Figure 1 BCL11A genomic, transcript and protein status in PMBLs and PMBL cell lines. In panel (a), the genomic amplification (PMBL 1) and the gain (PMBL 12) of BCL11A by FISH analysis (BCL11A (red; pooled BAC clones RP11-440P5 and RP11-158I21 labeled with Spectrum Orange (SO, Vysis, Downers Grove, IL, USA)) and REL (green; pooled BAC clones RP11-373L24 and PR11-498O5 or Alu-PCR products from CEPH-YAC clones 747H5 and 927G9 labeled with Spectrum Green (SG; Vysis))) are depicted. The transcript levels of BCL11A in the PMBLs, MedB-1 and Karpas1106 by qRT-PCR were placed into context using the transcript levels of three human tonsils referred to as the normal expression range indicated by the box (b). BCL11A XL protein expression of four PMBLs showed variable patterns by immunoperoxidase labelings irrespective of the genomic and transcriptional status (c). Bar represents 50 mm. a indicates amplified, g gained, and n normal genomic status.
assumed. In conclusion, the high frequency of BCL11A XLpositive PMBLs, as well as GCB-and ABC-DLBCL samples, emerges as a novel feature common to aggressive B-cell neoplasias.
BCL11A was found to directly interact with the class III histone deacetylase SIRT1, leading to transcriptional repression of a reporter gene construct. 8 In addition, BCL11A directly interacts with BCL6, 4 which is a transcriptional repressor implicated in germinal center formation and recurrently involved in chromosomal translocations in B-cell lymphomas. Notably, a correlation between the expression of BCL11A XL and BCL6 proteins has recently been reported in the majority of DLBCLs analyzed, 7 suggesting a concerted repressive interaction in DLBCL. In contrast, BCL6 protein was present in only 2/ 16 PMBLs analyzed (data not shown), providing a further characteristic of PMBL at variance with DLBCL. Cells of MedB-1 and Karpas1106, however, revealed weak BCL6 labeling in less than 10% and strong BCL6 labeling in approximately 40% of the cells, respectively.
To conclude, the BCL11A gene localized at the critical region 2p16 is genomically overrepresented in 75% of PMBLs. Furthermore, we observed nuclear BCL11A XL protein in 14/16 (87.5%) of PMBLs examined. The conspicuously high propensity of aggressive B-cell lymphomas, including PMBL, to express and accumulate nuclear BCL11A XL argues for an essential functional role of this repressor of transcription. Some but not all PMBLs attain this status by increasing their gene dosage, others obviously use alternative mechanisms. To gain further insight into this novel finding, interaction partners and target genes of BCL11A XL need to be identified.
